Alerts will be sent to your verified email
Verify EmailLINCOLN
Lincoln Pharma
|
Kwality Pharma
|
Wanbury
|
|
---|---|---|---|
Operational Metrics
|
|||
Pharmaceutical Sector
|
|||
Domestic Sales Growth - YoY
|
8.98 % | n/a | n/a |
R&D as a % of Total Sales
|
1.88 % | n/a | n/a |
Financials
|
|||
5 yr Average ROE
|
15.1 % | 25.27 % | -30.56 % |
5yr average Equity Multiplier
|
1.26 | 1.96 | -3.1 |
5yr Average Asset Turnover Ratio
|
0.82 | 1.05 | 1.51 |
5yr Avg Net Profit Margin
|
14.59 % | 11.66 % | 7.58 % |
Price to Book
|
1.59 | 3.55 | 14.71 |
P/E
|
12.37 | 21.61 | 20.29 |
5yr Avg Cash Conversion Cycle
|
-6.41 Days | 55.02 Days | -119.82 Days |
Inventory Days
|
43.91 Days | 67.04 Days | 20.62 Days |
Days Receivable
|
91.75 Days | 132.46 Days | 49.78 Days |
Days Payable
|
128.38 Days | 126.93 Days | 205.91 Days |
5yr Average Interest Coverage Ratio
|
63.13 | 16.13 | 2.36 |
5yr Avg ROCE
|
19.81 % | 34.73 % | -51.74 % |
5yr Avg Operating Profit Margin
|
18.35 % | 23.23 % | 4.22 % |
5 yr average Debt to Equity
|
0.0 | 0.46 | -0.61 |
5yr CAGR Net Profit
|
5.76 % | 21.34 % | -2.79 % |
5yr Average Return on Assets
|
11.92 % | 12.96 % | 11.1 % |
Shareholdings
|
|||
Promoter Holding
|
49.78 % | 54.83 % | 39.63 % |
Share Pledged by Promoters
|
0.0 | 0.0 | 76.74 % |
Change in Promoter Holding (3 Yrs)
|
5.7 % | 0.38 % | -0.22 % |
Change in Mutual Fund Holding (3 Yrs)
|
0.0 | 0.0 | 0.0 |
Lincoln Pharma
|
Kwality Pharma
|
Wanbury
|
|
---|---|---|---|
Product Wise Break-Up
|
Product Wise Break-Up
|
-
|
Product Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Location Wise Break-Up
|
Therapeutic Area Break-Up
|
Therapeutic Area Break-Up
|
-
|
-
|